Related Experiment Video
Updated: May 18, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
Development of a new scoring system for predicting the 5 year incidence of type 2 diabetes in Japan: the Toranomon
Y Heianza1, Y Arase, S D Hsieh
1Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Aims/Hypothesis:
The aims of this study were to assess the clinical significance of introducing HbA(1c) into a risk score for diabetes and to develop a scoring system to predict the 5 year incidence of diabetes in Japanese individuals.
Methods:
The study included 7,654 non-diabetic individuals aged 40-75 years. Incident diabetes was defined as fasting plasma glucose (FPG) ≥7.0 mmol/l, HbA(1c) ≥6.5% (48 mmol/mol) or self-reported clinician-diagnosed diabetes. We constructed a risk score using non-laboratory assessments (NLA) and evaluated improvements in risk prediction by adding elevated FPG, elevated HbA(1c) or both to NLA.
Results:
The discriminative ability of the NLA score (age, sex, family history of diabetes, current smoking and BMI) was 0.708. The difference in discrimination between the NLA + FPG and NLA + HbA(1c) scores was non-significant (0.836 vs 0.837; p = 0.898). A risk score including family history of diabetes, smoking, obesity and both FPG and HbA(1c) had the highest discrimination (0.887, 95% CI 0.871, 0.903). At an optimal cut-off point, sensitivity and specificity were high at 83.7% and 79.0%, respectively. After initial screening using NLA scores, subsequent information on either FPG or HbA(1c) resulted in a net reclassification improvement of 42.7% or 52.3%, respectively (p < 0.0001). When both were available, net reclassification improvement and integrated discrimination improvement were further improved at 56.7% (95% CI 47.3%, 66.1%) and 10.9% (9.7%, 12.1%), respectively.
Conclusions/Interpretation:
Information on HbA(1c) or FPG levels after initial screening by NLA can precisely refine diabetes risk reclassification.
Related Concept Videos
Type II Diabetes I: Introduction
Diabetes Mellitus: Type 2 and Gestational
Type II Diabetes II: Pathophysiology
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type I Diabetes I: Introduction
Type I Diabetes II: Pathophysiology